       Document 0822
 DOCN  M9620822
 TI    Regulated expression of a dominant negative form of Rev improves
       resistance to HIV replication in T cells.
 DT    9602
 AU    Liu J; Woffendin C; Yang ZY; Nabel GJ; Howard Hughes Medical Institute,
       University of Michigan Medical; Center, Department of Internal Medicine,
       Ann Arbor 48109-0650,; USA.
 SO    Gene Ther. 1994 Jan;1(1):32-7. Unique Identifier : AIDSLINE MED/96050917
 AB    Infection by the human immunodeficiency virus (HIV) has remained
       refractory to treatment, and molecular genetic interventions have been
       developed for the treatment of the acquired immunodeficiency syndrome
       (AIDS). Previous studies have focused on the development of gene
       products which inhibit productive HIV replication, including
       transdominant proteins, RNA decoys and ribozymes. In this report, we
       show that appropriate expression vectors which optimize production and
       regulated synthesis of a transdominant mutant form of Rev improve its
       antiviral effect. The combination of a strong constitutive enhancer, a
       Tat activation response (TAR) regulatory element and transdominant Rev
       take advantage of three aspects of early viral gene expression to confer
       increased resistance to HIV replication. This vector may be useful,
       alone or in combination with other antiviral genes, to provide gene
       therapy for AIDS.
 DE    Acquired Immunodeficiency Syndrome/THERAPY  Cells, Cultured  Enhancer
       Elements (Genetics)  *Gene Expression Regulation, Viral  Gene Therapy
       *Genes, rev  Genes, tat  Genes, Dominant  Genetic Vectors  Human
       HIV-1/*GENETICS/*PHYSIOLOGY  Mutation  Plasmids  T-Lymphocytes/*VIROLOGY
       Transfection  Virus Replication/*GENETICS  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

